Phd Student In Nanomedicine M/W

9 Sep 2023

Job Information

Organisation/Company

CNRS

Department

Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique

Research Field

Pharmacological sciences

Engineering

Technology

Researcher Profile

First Stage Researcher (R1)

Country

France

Application Deadline

29 Sep 2023 - 23:59 (UTC)

Type of Contract

Temporary

Job Status

Full-time

Hours Per Week

35

Offer Starting Date

15 Jan 2024

Is the job funded through the EU Research Framework Programme?

Not funded by an EU programme

Is the Job related to staff position within a Research Infrastructure?

No

Offer Description

The project will be carried out within the Laboratory of Tissue Biology and Therapeutic Engineering (LBTI – UMR 5305) in the “Colloidal vectors and targeted therapeutic engineering” team. The team's main projects focus on the design of therapeutic nanoformulations capable of crossing biological barriers with a focus on mucosal transport and immunity. It is important to emphasize that technical staff of the team have strong expertise on nanoparticle mRNA and antigen formulations, in vitro characterization, immunization protocols, serological tests (ELISA, Elispot) and analyzes histological studies dedicated to new vaccine approaches. Likewise, the LBTI benefits from a rich environment within the Lyon – Gerland bio-campus and new installations on the Lyon Santé East campus (main building at Rockefeller) of UCBL1 where this work will be carried out. The recruited person will be required to interact with the team located in Gerland (20 minutes by metro from Rockefeller).

Mucosal tissues are composed by a specialized epithelium covered by a mucus layer, and are the main portal of entry of most of pathogens. The induction of local (mucosal) immune response is highly desirable in order to effectively prevent mucosal infection and transmission, especially against rapidly emerging pathogens. The presence in the small intestine of Peyer's Patches (PP) as inductive sites of the gut-associated lymphoid tissue (GALT) makes the oral route of administration as a desirable approach to mucosal vaccination. However, the oral vaccine delivery needs to overcome some harsh conditions in the gastrointestinal tract (GIT) such as acid pH, degradation by digestive enzymes, low uptake across mucus layer, and immune tolerance. Lipid-polymer hybrid nanoparticles (NPs) allow the modification of surface properties to overcome the mucosal permeation barriers, enhanced physicochemical stability and drug protection during the transit through the GIT. The objective of SpheOrVac project is to conceive a robust mRNA delivery system able to bypass the GI barrier and to permit a mRNA expression, strong enough to induce a mucosal immune response. Our hypothesis is that by using a combination of dedicated lipids and polymers to form hybrid nanoparticles named Spheroplexes (Sphx), we could gather mRNA vectorization, adjuvant properties and muco-penetrating property in a unique delivery system able to induce a robust and long-lasting mucosal and systemic immune response following oral administration.

Requirements

Research Field

Pharmacological sciences

Education Level

PhD or equivalent

Research Field

Engineering

Education Level

PhD or equivalent

Research Field

Technology

Education Level

PhD or equivalent

Languages

FRENCH

Level

Basic

Research Field

Pharmacological sciences

Years of Research Experience

None

Research Field

Engineering

Years of Research Experience

None

Research Field

Technology

Years of Research Experience

None

Additional Information

Website for additional job details

https: // emploi.cnrs.fr/Offres/Doctorant/UMR5305-DANARR-001/Default.aspx

Work Location(s)

Number of offers available

1

Company/Institute

Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique

Country

France

City

LYON 07

Where to apply

Website

https: // emploi.cnrs.fr/Candidat/Offre/UMR5305-DANARR-001/Candidater.aspx

Contact

City

LYON 07

Website

https:// www. ibcp.fr

STATUS: EXPIRED